Beyond Biotech - the podcast from Labiotech

• Are mitochondrial therapeutics about to go mainstream?

  Mitochondria are famously the powerhouse of the cell, but will mitochondrial therapeutics power the next big mainstream medical breakthrough?Klaus Dugi is CEO of Vandria, a biotech that develops mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. He joins 'Beyond Biotech' to talk cell mitophagy, biotech agility, and innovation in tackling neurodegenerative disease.00:42    Introducing Klaus Dugi02:51    Lessons learned in top pharma05:10    The gap that Vandria seeks to fill06:21    Mitochondrial therapeutics07:45    Mitophagy inducers and how they work14:53    Comparing approaches to treating neurodegenerative diseases17:20    Aging, longevity, and healthy life years25:26    Challenges ahead27:31    Performance enhancement and resilience31:15    Towards the mainstream?34:35    Looking forward for Vandria36:02    Developments to watch out for in mitochondrial therapeuticsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

  --------  

  37:47
• Fighting Alzheimer's with innovative stem cell therapies

  Regeneration Biomedical has developed a new technique to address neurodegenerative diseases like Alzheimer's using stem cell therapy.Dr. Christopher Duma, has long been an innovator in neurosurgery using a gamma knife radiosurgery to treat glioblastoma. Now with Regeneration Biomedical, Duma is taking on neurodegenerative diseases with a first-in-human clinical trial where a patient's own stem cells are injected directly into their brain.On the podcast this week, we talk with Duma about his career in neurosurgery, the impetus for launching his biotech, the promise of stem cell therapy, and the challenges innovators face moving new therapies through the clinic.00:38    Introducing Dr Christopher Duma02:44    Advances and breakthroughs in neurosurgery05:33    The vision and impetus for Regeneration Biomedical10:45    Regeneration Biomedical’s R&D pipeline14:12    Milestones ahead14:46    Advancing beyond Alzheimer’s Disease15:52    Stems cells from fat cells19:42    Bypassing the blood-brain barrier22:45    Patient recruitment24:13    The treatment process27:10    The state of stem cell research in the US29:29    The challenge of financing innovative research32:15    Global stem cell research landscape33:14    Controversy in stem cell research34:00    Future horizons for Regeneration Biomedical37:23    Partnering with top pharma companies37:48    Advice for researchers and entrepreneursInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

  --------  

  41:51
• [Rebroadcast] How AI immune system mapping can boost drug discovery

  We’re taking a short break this week and, while we’re away, we invite you to enjoy one of our favorite episodes. We will return with a brand-new episode next week!Immunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering an affordable way to prevent expensive drug failures. The ultimate goal is to market immune treatments for diseases like cancer faster than ever before. In this week’s conversation, Noam Solomon, CEO and co-founder of Immunai, covers the data gap in drug discovery and how machine learning (ML) can solve it, how to de-risk early-stage drug discovery, predictions for AI, and more.00:49-01:13: About Immunai01:13-01:45: Why map the immune system?01:45-02:44: Are you taking a step back to study the problem in order to move forward?02:44-03:49: How difficult is it to map the immune system?03:49-05:29: What is your AMICA platform?05:29-07:24: Where does your data come from?07:24-09:09: How do you account for differences between patients?09:09-11:35: What are the biggest challenges to drug development?11:35-14:07: How can AI improve drug development?14:07-14:55: Will AI advances speed up drug development?14:55-16:06: Is the use of AI applicable in all diseases and conditions?16:06-17:48: What sets your approach apart from other companies using AI?17:48-18:54: What partnerships does Immunai have?18:54-20:24: What are pharma companies looking for from Immunai?20:24-23:17: How can AI help with clinical trials?23:17-24:32: Can AI help with preventative care?24:32-26:30: Google Maps for the immune system26:30-27:18: What will we see from AI in drug discovery in the short term?27:18-28:06: What are the next steps for Immunai?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

  --------  

  28:53
• The TCR-T cell therapies of tomorrow

  Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1.The CEO, Reagan Jarvis, when a researcher, pitched the company idea to a leading Swedish industrialist, who became co-founder, and provided the initial financing. The company has raised more than €100m to date.On the podcast this week, we have a conversation with Jarvis about TCR-T cell therapies, creating off-the-shelf products and partnerships with EmendoBio and Shinobi Therapeutics.00:43-02:10: About Anocca 02:10-04:16: About TCR-T cell therapies and their use in treatments04:16-06:02: Anocca’s approach to T-cell biology, cutting-edge biotechnologies and integrated software06:02-07:58: A different approach to other cell and gene therapy companies07:58-09:16: Facing challenges09:16-10:48: Addressing conditions and diseases10:48-11:54: Pancreatic cancer11:54-13:40: What represents success for Anocca?13:40-14:09: What is VIDAR-1?14:09-16:08: Partnerships16:08-18:05: Scaling up and addressing costs18:05-20:07: How is TCR-T therapy evolving?20:07-23:11: The impact of artificial intelligence23:11-25:16: Anocca timeline25:16-25:57: Closing comments  `Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

  --------  

  26:42
• Can RNA drugs solve the obesity epidemic?

  Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment.Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding RNA drug candidate that targets underlying biological pathways to promote sustainable weight loss. By enhancing energy expenditure through white-to-brown adipose tissue conversion while preserving muscle mass, RES-010 is positioned as an ideal standalone therapy or a synergistic option for long-term weight management.The company recently initiated a phase 1 study in December 2024 for RES-010 in healthy and obese subjects, and they also secured an equity investment from Sanofi in October 2024.To talk about ways to tackle obesity, and Resalis’ approach, our guest on the podcast this week is Alessandro Toniolo, CEO of Resalis Therapeutics.00:57-05:06: About Resalis Therapeutics05:06-08:59: Issues of obesity08:59-13:20: Companies working on obesity treatments13:20-15:34: Does suppressing appetite affect nutrition?15:34-17:49: Introduction of new obesity treatments17:49-21:33: Approaches other than appetite suppression21:33-22:38: RES-010 mode of action22:38-24:04: Administration methods24:04-25:11: Clinical trials25:11-26:38: Resalis’ pipeline26:38-28:08: Next steps for Resalis28:08-28:36: Effect of obesity on other parts of the body28:36-29:06: Final comments `Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

  --------  

  29:56

Więcej Wiadomości podcastów

Trendy w podcaście Wiadomości

O Beyond Biotech - the podcast from Labiotech